EMPLOYER ONSITE COLLECTIONS

On-demand biospecimen collection

Engage your employees to further scientific goals

200+	700+	135+	18	>90%
Healthy Participant Studies Completed	Onsite Employee Participants	Same-Day Studies Completed	Companies with Onsite Programs	Fulfillment Rate

Convenient

Fast and fresh specimens enable the best science

Streamlined, easy access to healthy samples

Fresh samples available immediately after collection

Experienced Provider

All informed consent, regulatory and IRB compliance managed on your behalf

Ensure the privacy of your employees through HIPAA compliance

Program setup within 8 weeks of contract

Flexible & Customizable

Specify I/E criteria

Support team manages logistics

Accommodate specimen collection-specific changes

Access the most convenient and expedient biospecimens on-site from your colleagues and address a plethora of research purposes. Establishing a hassle-free, full-service program at your office or laboratory offers a dependable and cost-efficient source for fast, on-demand healthy biospecimen collections. And offering your colleagues the opportunity to contribute to your organization's research creates a meaningful sense of purpose. Additionally, all employees will receive a gift card per donation.

YOU DESIGNATE A SMALL ONSITE SAMPLE COLLECTION ROOM, AND WE HANDLE THE REST:

- Assigned program support team
- Regulatory, HIPAA, and IRB protocol authorization
- Recruitment materials and website to promote participation
- Secure online portal for on-demand sample requests
- Quick turnaround from time of sample request (3–5 days)
- Electronic informed consent for donors
- Pre-screening according to defined I/E criteria
- Fully trained and equipped onsite phlebotomists
- Customization of collection tubes and anticoagulants
- Longitudinal collection for robust biomarker development

OUR PROGRAM COMPLIANCE PROTECTS YOUR EMPLOYEE DONORS:

FDA 21 CFR Part 11 | HIPAA COMPLIANT | ICH GOOD CLINICAL PRACTICES

818-462-8290 learnmore@sanguinebio.com www.sanguinebio.com

Sanguine

Case Studies: Doing Good Science with Your Onsite Program

Below are three published examples of biopharmaceutical companies leveraging their onsite programs to accomplish research and development initiatives. Please contact us at LearnMore@Sanguinebio.com to determine if an onsite program makes sense for your organization.

Establishing best practices for clinical trial protocols: PBMC processing

Problem

Peripheral blood mononuclear cells (PBMCs) are commonly analyzed for biomarkers in clinical trials, yet heterogeneous processing parameters (e.g., delays in isolation) can drastically affect results in unknown ways.

Sanguine Onsite Specimens

PBMCs were processed from whole blood (N=20):
- 2, 6, 24, and 48-hr time intervals since collection
- Methods: scRNA-seq, flow cytometry, ELISpot

*Fresh samples provided within 2 hours of collection

Insight

- PBMC viability was reduced after 48 hrs
- Granulocyte contamination increased after 24 hrs (flow cytometry)
- Gene expression correlations were <0.8 after 24 hr delay vs 2-4 hrs (scRNA-seq)
- Reduced IFN-γ secreting cells with increased delay (ELISpot)



Yi. (2023). J Immunol Methods. 519: 113514

"PBMC processing delays should be minimized when designing clinical trials to reduce outcome variability in downstream assays."

-Ping-Cheng Yi and colleagues, *Journal of Immunological Methods*

Gilead Sciences Inc., Foster City, CA

Screening healthy donor samples for specific immunology activity

Problem

To establish robust PK/PD data, donor whole blood needs to be screened to ensure specific biomarker assays report strong response signals in vitro.

Sanguine Onsite Specimens

Three donors out of a large pool of employee donors were chosen based on whole blood response to IL-23 stimulation to ensure at least 5-fold increase in pSTAT3 expression compared to unstimulated samples.

Insight

Sponsor's drug (Risankizumab) was shown to be equivalent or superior to three psoriasis-approved competitor IL-23 inhibitors:
- Highest affinity for and potent inhibition of IL-23
- Complete blockade of IL-23 binding to IL-23Rα
- Blocked terminal differentiation of TH17 cells
- More effective at reducing IL-17, IL-22, and keratinocyte gene expression



Zhou. (2021). mAbs. 13(1): e1964420.

Relevant preclinical assay results "shed light on the molecular attributes that may contribute to these antibodies' clinical efficacy."

-Li Zhou and colleagues, *mAbs*

AbbVie Bioresearch Center, Worcester, MA

Multipurpose utility of onsite-collected samples: Discovery biology % healthy controls

Experiment

Preclinical assays to determine: Why is adalimumab (Humira) the only anti- TNF therapy effective in Hidradenitis Suppurativa?

Sanguine Onsite Specimens

Monocytes were isolated from peripheral blood collected from healthy donors in the company's onsite program.

Result

Blood samples were used twofold:
1) to understand why the company's drug is the only anti- TNF therapy that is effective in a disease indication
2) healthy controls vs. patient samples collected in a clinical trial



Cao. (2021). J Invest Dermatol. 141(11): 2730-2740

"Our in vitro findings show that TNF-ADA-treated inflammatory macrophages exhibit a distinct profile resembling wound healing."

-Yonghao Cao and colleagues, *Journal of Investigative Dermatology*.

AbbVie Bioresearch Center, Worcester, MA